Archer Materials strategically expands access to institutional deep tech infrastructure

Archer Materials Ltd (ASX:AXE) (OTCMKTS:ARRXF) (FRA:38A) has strategically expanded its commercial access to institutional deep tech infrastructure as part of its biochip development.

This is expected to help overcome commercial and technological barriers to biochip development.

Archer is now directly accessing world-class analytical facilities with state-of-the-art, atom-scale quality control capabilities.

The infrastructure access is necessary to carry out the company’s biochip development and allows Archer to qualify its semiconductor device production processes as the company advances towards sub-10 nm biochip feature sizes.

“Access to world-class facilities”

Chief executive officer Dr Mohammad Choucair said: “We are very pleased to secure access to world-class facilities that would otherwise be extremely costly to purchase and operate ourselves.

“Archer’s growth has involved integrating the company’s early-stage tech development within institutional scale operations, and this ultimately translates to maintaining a strong cash position and no corporate debt.”

Shares have been almost 5% higher intra-day to A$0.90 while Archer’s market cap is approximately A$194.4 million.

Suite of institutional deep-tech 

The successful development of Archer’s biochip requires the analysis of semiconductor device materials components and the establishment of quality control processes at the nanoscale (one nanometre being a billionth of a metre).

This is because Archer’s biochip technology integrates materials like graphene, which is one-atom ‘thick’ in size.

There are very few instruments and facilities in the world today available to perform such sophisticated device and materials’ analysis on precision-engineered nanoscale devices.

Archer is utilising an outstanding suite of institutional deep tech infrastructure resources to directly analyse its prototype biochips, which builds on the company’s access to a A$150 million research and prototype semiconductor foundry where Archer fabricates its devices.

Precision nano-engineering of Archer’s biochip semiconductor devices is a global competitive advantage in the multibillion-dollar MedTech industry.

Story by ProactiveInvestors